Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

EHA 2017

22 - 25 Jun 2017
TBA, Madrid, Spain
4 years of RESONATE data for CLL patients treated with ibrutinib
Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona, S...
4 years of RESONATE data for CLL patients treated with ibrutinib ( Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )
28 Jun 2017
Latest maintenance strategies in multiple myeloma
Prof Guillermo Ruiz-Arguelles and Prof McCarthy
Latest maintenance strategies in multiple myeloma ( Prof Guillermo Ruiz-Arguelles and Prof McCarthy )
25 Jun 2017
Front-line combinations in multiple myeloma: Highlights from EHA 2017
Prof Joy Ho and Prof Je-Jung Lee
Front-line combinations in multiple myeloma: Highlights from EHA 2017 ( Prof Joy Ho and Prof Je-Jung Lee )
25 Jun 2017
Latest in relapsed and refractory multiple myeloma
Prof Heinz Ludwig, Prof Wee Joo Chng and Prof James Chim
Latest in relapsed and refractory multiple myeloma ( Prof Heinz Ludwig, Prof Wee Joo Chng and Prof James Chim )
25 Jun 2017
Lenalidomide with CD19 antibodies in L-MIND
Dr Kami Maddocks - Ohio State University, Columbus, USA
Lenalidomide with CD19 antibodies in L-MIND ( Dr Kami Maddocks - Ohio State University, Columbus, USA )
25 Jun 2017
The Myeloma XI trial - lenalidomide or thalidomide in triplet
Dr Charlotte Pawlyn - The Institute of Cancer Research, London, UK
The Myeloma XI trial - lenalidomide or thalidomide in triplet ( Dr Charlotte Pawlyn - The Institute of Cancer Research, London, UK )
25 Jun 2017
Denosumab or zoledronic acid for bone disease in multiple myeloma
Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece
Denosumab or zoledronic acid for bone disease in multiple myeloma ( Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece )
25 Jun 2017
Hemcare - multiple myeloma learning programme
Erik Aerts - President of HNHCP, Winterthur, Switzerland
Hemcare - multiple myeloma learning programme ( Erik Aerts - President of HNHCP, Winterthur, Switzerland )
24 Jun 2017
Extended followup indicates daratumumab with bortezomib and dexamethasone for re...
Prof Katja Weisel - University of Tübingen, Tübingen, Germany
Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )
24 Jun 2017
Enasidenib in mIDH relapsed and refractory AML
Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA
Enasidenib in mIDH relapsed and refractory AML ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )
24 Jun 2017
Impact of mutational profile at diagnosis for MDS/CML
Dr Guillermo Montalban Bravo - MD Anderson Cancer Center, Houston, USA
Impact of mutational profile at diagnosis for MDS/CML ( Dr Guillermo Montalban Bravo - MD Anderson Cancer Center, Houston, USA )
24 Jun 2017
Delayed infection exposure as a trigger for childhood ALL
Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany
Delayed infection exposure as a trigger for childhood ALL ( Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany )
24 Jun 2017
Triplet therapy for all comers in the CLL-BAG trial
Dr Paula Cramer – University of Cologne, Cologne, Germany
Triplet therapy for all comers in the CLL-BAG trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )
24 Jun 2017
The role of patient advocates in trial design, participation
Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy
The role of patient advocates in trial design, participation ( Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy )
24 Jun 2017
Disruption of BAFF-BCR crosstalk in CLL
Dr Alexey Danilov - Knight Cancer Institute, Portland, USA
Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )
24 Jun 2017
Phase Ib/II study of nivolumab in combination with azacytidine in patients with ...
Prof Naval Daver - MD Anderson Cancer Center, Houston, USA
Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML ( Prof Naval Daver - MD Anderson Cancer Center, Houston, USA )
24 Jun 2017
Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemi...
Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK
Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia ( Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK )
24 Jun 2017
Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia
Dr Max Topp - University of Wurzburg, Wurzburg, Germany
Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )
24 Jun 2017
Blood thinners a risk with cancer-associated venous thromboembolism
Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, ...
Blood thinners a risk with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )
24 Jun 2017
TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL
Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA
TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL ( Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA )
24 Jun 2017
FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma
Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany
FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma ( Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany )
24 Jun 2017
ZUMA 1: CD19 CAR T cells for refractory NHL
Dr Yi Lin, Mayo Clinic - Rochester, MN, USA
ZUMA 1: CD19 CAR T cells for refractory NHL ( Dr Yi Lin, Mayo Clinic - Rochester, MN, USA )
24 Jun 2017
Risk and benefit of anti-coagulants for elderly patients with cancer-associated ...
Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, ...
Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )
24 Jun 2017
Interim analysis of the JULIET study
Prof Gilles Salles - Université Claude Bernard, Lyon, France
Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )
24 Jun 2017
ZUMA1 trial of CD19 CAR T cells for aggressive NHL
Dr Yi Lin - Mayo Clinic, Rochester, USA
ZUMA1 trial of CD19 CAR T cells for aggressive NHL ( Dr Yi Lin - Mayo Clinic, Rochester, USA )
24 Jun 2017
400mg imatinib as good as 800mg for 10 year CML survival
Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany
400mg imatinib as good as 800mg for 10 year CML survival ( Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany )
23 Jun 2017
Carfilzomib combinations in ENDEAVOR and FORTE
Prof Katja Weisel - University of Tübingen, Tübingen, Germany
Carfilzomib combinations in ENDEAVOR and FORTE ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )
23 Jun 2017
Deep molecular response to gilteritinib in CHRYSALIS trial
Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern ...
Deep molecular response to gilteritinib in CHRYSALIS trial ( Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA )
23 Jun 2017
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib
Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017
Diverse T lymphocyte population fights leukaemia more effectively
Dr Michaela Kotrova - University Hospital Schleswig-Holstein, Kiel, Germany
Diverse T lymphocyte population fights leukaemia more effectively ( Dr Michaela Kotrova - University Hospital Schleswig-Holstein, Kiel, Germany )
23 Jun 2017
Delayed exposure to common infections causes acute childhood leukaemia
Dr Julia Hauer - Clinic for Pediatric Oncology, Haematology and Clinical Immunol...
Delayed exposure to common infections causes acute childhood leukaemia ( Dr Julia Hauer - Clinic for Pediatric Oncology, Haematology and Clinical Immunology, Düsseldorf, Germany )
23 Jun 2017
Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refrac...
Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017